Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

labatec pharma sa - propiverinum - gélules à libération modifiée - propiverini hydrochloridum 30 mg corresp. propiverinum 27.280 mg, acidum citricum, povidonum, lactosum monohydricum 5.667 mg, talcum, triethylis citras, magnesii stearas, acidi methacrylici et methylis methacrylatis polymerisatum 1:1, acidi methacrylici et methylis methacrylatis polymerisatum 1:2, ammonio methacrylatis copolymerum a, ammonio methacrylatis copolymerum b, matériel de la capsule: gelatina, e 171, e 172 (flavum), e 172 (rubrum), pro capsula. - incontinence et fréquence urinaire - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

labatec pharma sa - propiverini hydrochloridum - confetti - propiverini hydrochloridum 5 mg, lactosum monohydricum 33.56 mg, cellulosi pulvis, magnesii stearas, pellicule: saccharum 24.49 mg, talcum, kaolinum ponderosum, calcii carbonas, acaciae gummi, silica colloidalis anhydrica, macrogolum 6000, glucosum monohydricum 0.31 mg, e 171, pro compresso obducto. - incontinence et fréquence urinaire et urgence urinaire - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - fingolimodum - capsule - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, amylum pregelificatum, natrii laurilsulfas corresp. natrium 0.045 mg, kapselhülle: e 171, e 172 (flavum), gelatina, drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 172 (nigrum), kalii hydroxidum, pro capsula. - multiple sklerose - synthetika

Den Europæiske Union - italiensk - EMA (European Medicines Agency)

mylan ireland limited - fingolimod cloridrato - sclerosi multipla recidivante-remittente - immunosoppressori - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 e 5. 1)orpatients con rapida evoluzione grave, recidivante remittente della sclerosi multipla definita da 2 o più invalidante recidive in un anno, e con 1 o più gadolinio migliorare lesioni alla risonanza magnetica cerebrale o un aumento significativo della lesione t2 carico rispetto ad un precedente recente rm.

Italien - italiensk - AIFA (Agenzia Italiana del Farmaco)

bausch health ireland limited -

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

labatec pharma sa - propiverinum - gélules à libération modifiée - propiverini hydrochloridum 45 mg corresp. propiverinum 40.92 mg, acidum citricum, povidonum, lactosum monohydricum 8.5 mg, talcum, triethylis citras, magnesii stearas, acidi methacrylici et methylis methacrylatis polymerisatum 1:1, acidi methacrylici et methylis methacrylatis polymerisatum 1:2, ammonio methacrylatis copolymerum a, ammonio methacrylatis copolymerum b, matériel de la capsule: gelatina, e 171, e 172 (rubrum), e 172 (flavum), pro capsula. - incontinence, fréquence urinaire et urgence urinaire - synthetika

Den Europæiske Union - italiensk - EMA (European Medicines Agency)

mylan ireland limited - fingolimod cloridrato - sclerosi multipla recidivante-remittente - immunosoppressori - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 e 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - fingolimodum - capsule - fingolimodum 0.25 mg ut fingolimodi hydrochloridum, amylum pregelificatum, natrii laurilsulfas corresp. natrium < 23 mg, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 172 (nigrum), kalii hydroxidum pro capsula. - multiple sklerose - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - fingolimodum - capsule - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, amylum pregelificatum, natrii laurilsulfas corresp. natrium < 23 mg, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 172 (nigrum), kalii hydroxidum pro capsula. - multiple sklerose - synthetika

Italien - italiensk - AIFA (Agenzia Italiana del Farmaco)

medac pharma srl -